Table 3.

Frequency of non-CAEs in ponatinib-treated patients

Non-CAEs	Cumulative incidence, n (%) (n = 78)	Ponatinib 45 mg/d, n (%)	Ponatinib 30 mg/d, n (%)	Ponatinib 15 mg/d, n (%)
Thrombocytopenia	31 (39.7)	18 (23.1)	10 (12.8)	3 (3.8)
Abdominal pain	26 (33.3)	16 (20.5)	7 (9.0)	3 (3.8)
Anemia	22 (28.2)	16 (20.5)	4 (5.1)	2 (2.6)
Elevated lipase	22 (28.2)	11 (14.1)	9 (11.5)	2 (2.6)
Rash	21 (26.9)	13 (16.7)	6 (7.7)	2 (2.6)
Neutropenia	16 (20.5)	12 (15.4)	2 (2.6)	2 (2.6)
Pancreatitis	8 (10.3)	5 (6.4)	3 (3.8)	0 (0.0)
Diabetes Mellitus	2 (2.6)	1 (1.3)	1 (1.3)	0 (0.0)